TECENTRIQ HYBREZA
TECENTRIQ HYBREZA is a combination of atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody, and hyaluronidase, an endoglycosidase. It is indicated for the treatment of adult patients with various stages of non-small cell lung cancer (NSCLC), including adjuvant treatment for early-stage disease and first-line or subsequent treatment for metastatic disease. Additionally, it is used in the treatment of extensive-stage small cell lung cancer (ES-SCLC) as both a first-line and maintenance therapy. The drug is often administered in combination with chemotherapy or other targeted agents based on the patient's specific cancer type and PD-L1 expression levels.
How TECENTRIQ HYBREZA Works
Atezolizumab binds to PD-L1 on tumor cells and immune cells, preventing it from interacting with PD-1 and B7.1 receptors on T-cells. This blockade releases the inhibition of the immune system, allowing for the activation of anti-tumor immune responses, including increased T-cell activity and proliferation. The hyaluronidase component functions by depolymerizing hyaluronan, a polysaccharide in the subcutaneous tissue's extracellular matrix. This action transiently increases the permeability of the subcutaneous tissue, facilitating the local delivery and absorption of the medication.
Details
- Status
- Prescription
- First Approved
- 2024-09-12
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
TECENTRIQ HYBREZA Approval History
What TECENTRIQ HYBREZA Treats
1 indicationsTECENTRIQ HYBREZA is approved for 1 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Non-Small Cell Lung Cancer
TECENTRIQ HYBREZA Target & Pathway
ProTarget
An immune checkpoint receptor on T-cells that acts as an 'off switch' for immune responses. Cancer cells often exploit PD-1 by expressing its ligands (PD-L1/PD-L2), allowing tumors to evade immune detection. Blocking PD-1 releases this brake, enabling T-cells to recognize and attack cancer cells.
Pathway Context
PD-1 on T-cells binds to PD-L1/PD-L2 on tumor cells, suppressing immune attack
A protein expressed on tumor cells and immune cells that binds to PD-1 on T-cells, suppressing immune responses. Many cancers overexpress PD-L1 to avoid immune attack. Blocking PD-L1 prevents this immune suppression, allowing the body's T-cells to fight cancer.
A second ligand for PD-1, expressed on antigen-presenting cells and some tumors. PD-L2 binds PD-1 with higher affinity than PD-L1 but is less widely expressed. Drugs blocking PD-1 prevent both PD-L1 and PD-L2 interactions.
TECENTRIQ HYBREZA Competitors
Pro10 other drugs also target PD-1. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (PD-1). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to TECENTRIQ HYBREZA
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
TECENTRIQ HYBREZA FDA Label Details
ProIndications & Usage
FDA Label (PDF)TECENTRIQ HYBREZA is a combination of atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody, and hyaluronidase, an endoglycosidase indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test. for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltratin...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.